HCG Manavata Cancer Centre Introduces PIPAC Surgery in Nashik, While Sarvodaya Hospital, Faridabad Becomes First in India to Offer Terbium-161 PSMA Therapy for Prostate Cancer.

In a dual advancement for India’s cancer care landscape, two premier healthcare institutions—HCG Manavata Cancer Centre (HCGMCC) in Nashik and Sarvodaya Hospital in Faridabad—have announced breakthrough initiatives in minimally invasive and nuclear medicine-based oncology treatments. These developments mark significant progress in offering precision care and new hope to patients battling advanced-stage cancers.

HCG Manavata Cancer Centre Ushers in PIPAC Surgery in North Maharashtra

HCG Manavata Cancer Centre has successfully performed North Maharashtra’s first-ever Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) surgery on a patient with advanced gastric cancer. This state-of-the-art, minimally invasive procedure is gaining global acceptance for treating peritoneal metastases—cancers originating from the stomach, ovaries, and colon that spread to the abdominal lining.

Conducted under the expert supervision of Dr. Ninad Katdare of HCG Cancer Centre Mumbai and Prof. Dr. Raj Nagarkar, Managing Director & Chief of Surgical Oncology and Robotic Services at HCGMCC, the procedure showcases a collaborative clinical approach to pushing boundaries in regional cancer care.

“PIPAC is transforming the management of advanced abdominal cancers,” said Dr. Nagarkar. “By delivering aerosolised chemotherapy directly into the peritoneal cavity under pressure, we are enhancing drug penetration, improving treatment efficacy, and minimising systemic side effects—all while ensuring quicker recovery for patients.”

With over 70,000 surgeries to his credit, Dr. Nagarkar emphasised PIPAC’s synergy with other treatment modalities such as systemic chemotherapy and immunotherapy, making it a robust addition to modern oncological practice.

Sarvodaya Hospital Launches India’s First Terbium-161 PSMA Therapy for Prostate Cancer

Meanwhile, in a landmark move for nuclear medicine, Sarvodaya Hospital, Faridabad has become the first centre in India to introduce Terbium-161 PSMA (Prostate-Specific Membrane Antigen) therapy for patients with advanced, metastatic prostate cancer.

Under the leadership of Dr. Swagat Dash, HOD & Senior Consultant of Nuclear Medicine at Sarvodaya Cancer Institute, the facility now provides an innovative theranostic option that combines diagnostic imaging with targeted radionuclide therapy. Terbium-161’s high efficacy in targeting prostate tumors offers new therapeutic avenues for patients with castration-resistant or hormone-refractory conditions.

“This marks a transformative step in precision oncology,” said Dr. Swagat Dash. “We are proud to pioneer this in India, enabling highly targeted treatment with improved outcomes for patients who otherwise have limited options.”

Additionally, Dr. Dinesh Pendharkar, Director of Sarvodaya Cancer Institute, announced the integration of CAR-T Cell Therapy into the hospital’s oncology portfolio, reinforcing the institution’s status as a comprehensive cancer care provider.

Elevating India’s Cancer Care Infrastructure

Both initiatives reflect the ongoing evolution of India’s cancer care infrastructure towards personalised, tech-enabled, and globally benchmarked solutions. While HCGMCC’s adoption of PIPAC brings global best practices to Tier-II cities, Sarvodaya Hospital’s introduction of Terbium-161 PSMA therapy underscores India’s readiness to lead in nuclear medicine and theranostics.

These advancements also highlight the collaborative spirit and clinical excellence that define India’s healthcare ecosystem. They promise improved survival rates, enhanced quality of life, and a new era of patient-centric treatment pathways for complex cancers.

As India continues to adopt and innovate in oncology, these milestones serve as blueprints for other institutions aiming to deliver cutting-edge care and make world-class treatment accessible beyond metropolitan hubs.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!